|
There are many biologics in the development pipeline for whom stability during manufacture and in storage are significant issues. Recombinant proteins, single chain antibodies, fusion proteins, nucleic acids and vaccines are often plagued with the challenge of overcoming unwanted instabilities. Consequently some promising therapeutic candidates never make it beyond early development phase for want of a stable formulation acceptable to the pharmaceutical industry.
Arecor has demonstrated that biologics considered difficult to formulate can be progressed as development candidates through the application of Arestat™ technologies. One such case involved a single chain antibody showing therapeutic promise but an unacceptable stability profile. Through the application of Arestat-T™ technology Arecor has been able to overcome the instability allowing the product to be considered as a clinical candidate. |
|
ArestatTM comprises two fundamentally different aspects of our platform stabilization technology. Both utilize excipients and buffers approved by the FDA and EMEA in an unconventional manner to achieve the desired stability
Both platform technologies are available for licensing for applications involving therapeutic proteins, vaccines, medical devices and diagnostics
|
